Bridge Biotherapeutics Stock Total Debt
| 288330 Stock | KRW 3,940 120.00 2.96% |
Bridge Biotherapeutics fundamentals help investors to digest information that contributes to Bridge Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Bridge Stock. The fundamental analysis module provides a way to measure Bridge Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bridge Biotherapeutics stock.
Bridge |
Bridge Biotherapeutics Company Total Debt Analysis
Bridge Biotherapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Bridge Biotherapeutics Total Debt | 53.63 M |
Most of Bridge Biotherapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bridge Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Bridge Biotherapeutics has a Total Debt of 53.63 M. This is 98.05% lower than that of the Healthcare sector and significantly higher than that of the Biotechnology & Medical Research industry. The total debt for all Republic of Korea stocks is 98.99% higher than that of the company.
Bridge Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bridge Biotherapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bridge Biotherapeutics could also be used in its relative valuation, which is a method of valuing Bridge Biotherapeutics by comparing valuation metrics of similar companies.Bridge Biotherapeutics is rated fourth in total debt category among its peers.
Bridge Fundamentals
| Return On Equity | -75.4 | |||
| Current Valuation | 29.26 B | |||
| Shares Owned By Insiders | 30.27 % | |||
| Shares Owned By Institutions | 9.09 % | |||
| Revenue | 1.92 B | |||
| Gross Profit | (1.12 B) | |||
| EBITDA | (21.27 B) | |||
| Net Income | (26.28 B) | |||
| Cash And Equivalents | 8.2 B | |||
| Total Debt | 53.63 M | |||
| Current Ratio | 1.05 X | |||
| Cash Flow From Operations | (21.13 B) | |||
| Market Capitalization | 217.07 B | |||
| Total Asset | 46.66 B | |||
| Net Asset | 46.66 B |
About Bridge Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bridge Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bridge Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bridge Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bridge Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bridge Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bridge Stock
Moving against Bridge Stock
| 0.56 | 041510 | SM Entertainment | PairCorr |
| 0.56 | 032640 | LG Uplus | PairCorr |
| 0.54 | 035420 | Naver | PairCorr |
| 0.39 | 078160 | MEDIPOST | PairCorr |
| 0.36 | 011390 | Busan Industrial | PairCorr |
The ability to find closely correlated positions to Bridge Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bridge Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bridge Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bridge Biotherapeutics to buy it.
The correlation of Bridge Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bridge Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bridge Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bridge Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.